About enGene Holdings Inc.
https://www.engene.comenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
CEO
Ronald H. W. Cooper
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Oppenheimer
Outperform
Morgan Stanley
Overweight
UBS
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FCPM III SERVICES B.V.
Shares:9.63M
Value:$87.66M
VR ADVISER, LLC
Shares:5.05M
Value:$45.92M
KYNAM CAPITAL MANAGEMENT, LP
Shares:4.99M
Value:$45.45M
Summary
Showing Top 3 of 42
About enGene Holdings Inc.
https://www.engene.comenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $39.31M ▲ | $-37.88M ▼ | 0% | $-0.74 ▼ | $-37.46M ▼ |
| Q3-2025 | $0 | $29.95M ▲ | $-28.99M ▼ | 0% | $-0.57 ▼ | $-27.86M ▼ |
| Q2-2025 | $0 | $27.12M ▲ | $25.82M ▲ | 0% | $0.51 ▲ | $-24.73M ▼ |
| Q1-2025 | $0 ▼ | $26.61M ▲ | $-24.62M ▼ | 0% ▲ | $-0.48 ▼ | $-23.74M ▼ |
| Q4-2024 | $480K | $17.45M | $-15.3M | -3.19K% | $-0.34 | $-14.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $193.81M ▼ | $221.47M ▼ | $53.76M ▲ | $167.71M ▼ |
| Q3-2025 | $201.99M ▼ | $245.55M ▼ | $44.88M ▲ | $200.67M ▼ |
| Q2-2025 | $217.46M ▲ | $266.65M ▼ | $39.36M ▲ | $227.29M ▼ |
| Q1-2025 | $213.89M ▼ | $285.93M ▼ | $35.98M ▼ | $249.95M ▼ |
| Q4-2024 | $238.4M | $311.17M | $38.56M | $272.61M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-37.88M ▼ | $-24.96M ▲ | $40.5M ▲ | $1.99M ▲ | $17.53M ▲ | $-25.4M ▲ |
| Q3-2025 | $-28.99M ▼ | $-25.63M ▼ | $1.38M ▼ | $-667K ▼ | $-24.92M ▼ | $-26.34M ▼ |
| Q2-2025 | $-25.82M ▼ | $-22.95M ▲ | $17.95M ▲ | $199K ▲ | $-4.8M ▲ | $-22.99M ▲ |
| Q1-2025 | $-24.62M ▼ | $-25.7M ▼ | $-84.96M ▲ | $1K ▼ | $-110.66M ▼ | $-26M ▼ |
| Q4-2024 | $-15.3M | $-19.57M | $-125.27M | $60.16M | $-84.67M | $-19.81M |
CEO
Ronald H. W. Cooper
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Oppenheimer
Outperform
Morgan Stanley
Overweight
UBS
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FCPM III SERVICES B.V.
Shares:9.63M
Value:$87.66M
VR ADVISER, LLC
Shares:5.05M
Value:$45.92M
KYNAM CAPITAL MANAGEMENT, LP
Shares:4.99M
Value:$45.45M
Summary
Showing Top 3 of 42